By Jacob Gronholt-Pedersen and Maggie Fick
COPENHAGEN (Reuters) – Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it hopes will show greater weight-loss, after posting disappointing late-stage trial data.
“We plan to optimise dose titration to further explore CagriSema’s additional weight loss potential with a new trial planned to start in the first half of 2025,” a company spokesperson said in an email to Reuters.
The spokesperson did not answer further questions on whether Novo would change the relative proportions of the two molecules, cagrilintide and semaglutide, that are combined into the CagriSema injection.
“The protocol of the new planned trial will come out in 2025,” the spokesperson said.
Earlier on Friday, Novo said CagriSema helped patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off its market value.
(Reporting by Jacob Gronholt-Pedersen and Maggie Fick, editing by Louise Breusch Rasmussen and Jane Merriman)
